KLA-Tencor Corporation (NASDAQ:KLAC)
KLA-Tencor Corporation (NASDAQ:KLAC) represented a move of 0.56 percent or $-1.34 per share and closed its previous day trading session at $97.05. 1.42 Million Shares were traded in the last trading session with an Average Volume of 1.77 Million Shares. The stock currently has a Market Capitalization of 15.29 Billion.
KLA-Tencor was formed through the merger of KLA Instruments (KLA) and Tencor Instruments (Tencor), two long-time leaders in the semiconductor equipment and yield management software system industry. Prior to the merger, both businesses served a segment of the inspection and metrology area; with KLA focused on defect inspection solutions and Tencor placing its emphasis on metrology solutions. Merging together in a one-to-one stock swap valued at $1.3 billion, KLA-Tencor became the most important process control player in the industry, bringing to market a complete line of yield management products and services from a single company.
The stock traded between $ 84.59 and $123.96 over 1-Year time period showing its price to sales ratio of 3.67. KLA-Tencor Corporation (NASDAQ:KLAC) is currently showing an INCREASING volatility over a period of 10-Days while the 20-Days Volatility showing a INCREASING trend.
Right now, the stock has a 50-Day Simple Moving Average of $-2.46 and 200-Day Simple Moving Average of $-9.68. Its Price to Free Cash Flow is 20.69 and Price to Book of 9.61.
Analyst’s recommended the stock as 2 where 1 represents Strong Buy and 5 represents Sell.
In the last Quarter, KLA-Tencor Corporation (NASDAQ:KLAC) reported its Actual EPS of $2.46/share. The analysts offering Earnings Estimates for the company were believing that KLA-Tencor Corporation could bring EPS of $2.21/share. The difference between Actual EPS and Estimated EPS was 0.25 Percent. Thus showing an Earnings Surprise of 11.3 Percent.
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
In the last trading session, Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) added its value by -3.96% closing at the price of $73.04. The stock currently has market capitalization of 7.34 Billion, with average volume of 980.14 Million shares.
Beta is also a factor of measure of the relative volatility of a particular stock to the market. Currently Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is showing beta of 2.54. This particular value of beta suggests that Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) has historically moved 254% for every 100% move in the benchmark, based on price level.
EPS is another important factor while making the decision of buying, selling or holding of particular share. Currently EPS for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is at $-5.87.
The stock currently has RSI of 37.56. RSI is considered overbought when above 70 and oversold when below 30, currently the given RSI for the stock suggests that the stock is average and it has not entered in overbought or oversold territory.
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. The company is applying its therapeutic expertise in RNAi to address significant medical needs, many of which cannot effectively be addressed with small molecules or antibodies, the current major classes of drugs. Alnylam is building a pipeline of RNAi therapeutics; its lead program is in Phase I human clinical trials for the treatment of respiratory syncytial virus infection, which is the leading cause of hospitalization in infants in the U.S. The company’s leadership position in fundamental patents, technology, and know-how relating to RNAi has enabled it to form major alliances with leading companies including Merck, Medtronic, Novartis, and Biogen Idec.
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) topped its 52-week high price of $153.99 on 03/20/18 and 52-Week Low Price of $ 71.85 on 10/24/18. The Stock currently has P/E (price to earnings ttm) of 0 and Weekly volatility of 6.66% and monthly volatility of 5.81% respectively.